Search for a new target therapy in the advanced prostate cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592398
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: University of Miyazaki
• Principal Investigator: KAMOTO Toshiyuki 宮崎大学, 医学部, 教授 (00281098)
• Co-Investigator(Kenkyū-buntansha): MORISHITA Kazuhiro 宮崎大学, 医学部機能制御学講座腫瘍生化学分野, 教授 (80260321) ; MUKAI Shoichiro 宮崎大学, 医学部外科学講座 泌尿器科学分野, 講師 (10315369) ; SUGIE Satoru 宮崎大学, 医学部外科学講座泌尿器科学分野, 医員 (50626140)
• Research Collaborator: TSUKINO Hiromasa 宮崎大学, 医学部外科学講座泌尿器科学分野, 講師 (60433059) ; KAMIBEPPU Toyoharu 宮崎大学, 医学部外科学講座泌尿器科学分野, 医員 (90649641)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 前立腺 / シグナル伝達

Outline of Final Research Achievements

We evaluated associations between plasma CAV1 levels and prostate cancer in Japanese men, and CAV1 expression in PC3 and LNCaP cell lines. As a results, plasma CAV1 levels in patients with CRPC were much higher than in those with non-CRPC(p<0.004). In vitro analyses showed CAV1 protein and mRNA in PC3 cells to be significantly overexpressed compared to that in LNCaP cells (p<0.0001).In conclusion, our results support the possibility of CAV1 as a therapeutic target for CRPC. And then, we evaluated the relationship between the CAV1 T29107A polymorphism and the risk of prostate cancer among Japanese populations. As a results, logistic regression analysis of case and control outcomes showed an odds ratio of 0.35 (p=0.033) between the TT and AA polymorphisms, indicating a reduced risk of prostate cancer to be associated with the AA polymorphism. Our results support the hypothesis that this polymorphism may influence susceptibility to prostate cancer.

Free Research Field

癌